Skip to main content

21.06.2017 | Biomarkers of Heart Failure (W.H.W. Tang and J.L. Grodin, Section Editors) | Ausgabe 4/2017

Current Heart Failure Reports 4/2017

Novel Biomarkers of Subclinical Cardiac Dysfunction in the General Population

Current Heart Failure Reports > Ausgabe 4/2017
Kamal Shemisa, Anish Bhatt, Daniel Cheeran, Ian J. Neeland
Wichtige Hinweise
Kamal Shemisa, Anish Bhatt, and Daniel Cheeran contributed equally to this article.
This article is part of the Topical Collection on Biomarkers of Heart Failure


Purpose of Review

Recognition of subclinical myocardial dysfunction offers clinicians and patients an opportunity for early intervention and prevention of symptomatic cardiovascular disease. We review the data on novel biomarkers in subclinical heart disease in the general population with a focus on pathophysiology, recent observational or trial data, and potential applicability and pitfalls for clinical use.

Recent Findings

High-sensitivity cardiac troponin and natriuretic peptide assays are powerful markers of subclinical cardiac disease. Elevated levels of these biomarkers signify subclinical cardiac injury and hemodynamic stress and portend an adverse prognosis. Novel biomarkers of myocardial inflammation, fibrosis, and abnormal contraction are gaining momentum as predictors for incident heart failure, providing new insight into pathophysiologic mechanisms of cardiac disease.


There has been exciting growth in both traditional and novel biomarkers of subclinical cardiac injury in recent years. Many biomarkers have demonstrated associations with relevant cardiovascular outcomes and may enhance the diagnostic and prognostic power of more conventional biomarkers. However, their use in “prime time” to identify patients with or at risk for subclinical cardiac dysfunction in the general population remains an open question. Strategic investigation into their clinical applicability in the context of clinical trials remains an area of ongoing investigation.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Über diesen Artikel

Weitere Artikel der Ausgabe 4/2017

Current Heart Failure Reports 4/2017 Zur Ausgabe

Comorbidities of Heart Failure (C Angermann and F Edelmann, Section Editors)

Inflammation – Cause or Consequence of Heart Failure or Both?

Biomarkers of Heart Failure (W.H.W. Tang and J.L. Grodin, Section Editors)

The Basic Metabolic Profile in Heart Failure—Marker and Modifier

Pathophysiology of Myocardial Failure (Inder Anand and Maria Patarroyo-Aponte, Section Editors)

SGLT-2 Inhibitors in Heart Failure: Implications for the Kidneys

Clinical Trials (J Butler, Section Editor)

Novel Endpoints for Heart Failure Clinical Trials

  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Kardiologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Kardiologie und bleiben Sie gut informiert – ganz bequem per eMail.